MS
IDYA icon

Maven Securities’s IDEAYA Biosciences IDYA Stock Holding History

Maven Securities’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-72,464
Closed -$1.03M – 676
2020
Q2 		$1.03M Buy
+72,464
New +$571K 0.07% 209

Other funds holding IDYA

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Maven Securities's IDYA Position: Q3 2020 in Review

Maven Securities sold out of IDEAYA Biosciences (IDYA) in Q3 2020, closing a stake of 72,464 shares — an estimated $1.03M sold.

Maven Securities first reported a position in IDYA in Q2 2020 and held it in 1 quarter. The position peaked at $1.03M in Q2 2020. 68 funds tracked by Wall St. Rank hold IDYA as of Q3 2020.

  • Maven Securities reported no remaining IDEAYA Biosciences position as of Q3 2020 after selling out during the quarter.
  • Maven Securities sold 72,464 IDEAYA Biosciences shares in Q3 2020, an estimated $1.03M.
  • Maven Securities first reported a position in IDEAYA Biosciences in Q2 2020 and held it in 1 quarter.
  • Maven Securities's IDEAYA Biosciences position peaked at $1.03M in Q2 2020.
  • 68 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q3 2020.

Based on Maven Securities's 13F filing for Q3 2020, filed 13 Nov 2020.